Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Shionogi’s COVID Pill Up for PAFSC Review for 1st Emergency Approval
June 16, 2022
-
REGULATORY Japan to Create Expert Panel to Ponder Drug Distribution and Pricing: Kanmin Taiwa
June 15, 2022
-
REGULATORY Japan to Launch New Agency for Pandemic Responses, Eyes MHLW Rejig
June 15, 2022
-
BUSINESS Authorized Generics Gain Ground amid Quality Woes, Candesartan AG Share Up 10 Points
June 14, 2022
-
REGULATORY MSD’s Two-Time PMP Appeals for Lyfnua Rejected: DPO Minutes
June 14, 2022
-
ORGANIZATION FPMAJ Pushes Minimal Product Scope for Off-Year Re-Pricing, No Cut in 2% Buffer Zone: Annual Report
June 13, 2022
-
REGULATORY “Re-Do” Pricing Based on New Assumption Rather than Simple Cuts, DPP Lawmaker Says on Re-Pricing Rules
June 10, 2022
-
BUSINESS Idorsia Japan Set to File Its 2nd and 3rd Drugs Early Next Year, Eyes 80 Billion Yen Sales in 5 Years
June 9, 2022
-
BUSINESS Novartis Sees CML Med Scemblix as Growth Driver over Next Decade, 1st Line Use Holds Key
June 8, 2022
-
REGULATORY Japan OKs Honebuto Paper with No Mention of Drug Pricing; Stable Supply, Innovation, Biosimilar Promotion Spelled Out
June 8, 2022
-
REGULATORY Pharmacist LDP Candidate Eager for National Debate on Drug Pricing
June 7, 2022
-
REGULATORY Public-Private Confab Set for June 14, Talks on Data Utilization Expected
June 7, 2022
-
REGULATORY Scrap All Barriers, Annual Drug Re-Pricing to Boost International Competitiveness of Japan Pharma: LDP’s Jimi
June 6, 2022
-
BUSINESS Gilead Japan Eyes High-Single-Digit Annual Growth with Oncology as Third Biz Pillar
June 3, 2022
-
COMMENTARY New Zero Premium Rule Applied to 6 Drugs Since April Rollout, Is It Incentivizing Cost Disclosure?
June 2, 2022
-
BUSINESS Shashank Deshpande to Take Reins at Nippon Boehringer Ingelheim
June 2, 2022
-
REGULATORY Honebuto Draft Makes No Mention of Off-Year Re-Pricing or Buffer Zone, Calls for Stronger Drug Discovery Capabilities
June 1, 2022
-
BUSINESS Takeda to Transfer Spikevax Authorization to Moderna in Japan, 3-Way Purchase Deal to End
June 1, 2022
-
ACADEMIA NCGM, IQVIA Pair Up to Unravel “Long COVID” by Building Large-Scale Registry
May 31, 2022
-
REGULATORY Janssen’s COVID-19 Vaccine in Line for Japan Approval, No Supply Deal Signed
May 31, 2022
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…